Matches in SemOpenAlex for { <https://semopenalex.org/work/W2232423692> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2232423692 abstract "20007 Background: Allo SCT may benefit patients with R/R HD by providing a graft vs lymphoma effect. Peggs et al (Lancet 2005) demonstrated durable engraftment and reduced non relapse mortality (NRM) in HD pts post RI Allo SCT. Carella et al (JCO2000) and Gutman et al (BMT2005) demonstrated the success of MA Auto SCT followed by RI AlloSCT in adults with refractory lymphoma. We investigated the feasibility of MA Auto SCT followed by RI Allo SCT in children with R/R HD. Methods: MA conditioning prior to AutoSCT was CTX 1,500 mg/m 2 x 4 d, BCNU 100 mg/m 2 x 3d, VP-16 800 mg/m 2 x 3d. AlloSCT conditioning was fludarabine 30 mg/m 2 x 5d, busulfan 3.2 mg/kg x 2d, and R ATG 2 mg/kg x 4d (unrel. donor). CD20+ patients received rituximab (375 mg/m 2 /wk x4) and all pts received involved field radiotherapy (IFRT). Results: Ten pts have enrolled, 2 pts did not proceed (parental withdrawal) to RI AlloSCT (Donors: 1 MRD, 2 MUD, 5 UCB). Median time to RI AlloSCT after MA Auto SCT was 142 d (97–219). The median cell dose was 3.43 x 10 7 TNC/kg for UCB grafts (n=5). Engraftment was achieved at a median of 20.5 d for PMN and 46.5 d for PLT. Donor chimerism reached ≥ 95% in all pts by day 100 with a median follow up of 703d (128–2025). Toxicities were grade (3) hematuria (n=1), (3–4) infection (n=7), (4) pulmonary fibrosis (n=1), (4) hearing loss (n=1), (4) neurotoxicity (n=1). GVHD: grade II-III aGVHD (3/8), cGVHD (3/8). Six patients are alive and NED post allo SCT. There has been one NRM (cGVHD) and one relapse mortality. The OS at one year is 66.7%. Conclusions: MA AutoSCT followed by RI AlloSCT is feasible and well tolerated in pediatric pts with R/R HD. A larger study with longer follow up is required to determine if this approach will reduce relapse, long term toxicity and/or improve survival. No significant financial relationships to disclose." @default.
- W2232423692 created "2016-06-24" @default.
- W2232423692 creator A5001697191 @default.
- W2232423692 creator A5019068922 @default.
- W2232423692 creator A5033104475 @default.
- W2232423692 creator A5048733835 @default.
- W2232423692 creator A5049279048 @default.
- W2232423692 creator A5051296786 @default.
- W2232423692 creator A5060384074 @default.
- W2232423692 creator A5066588983 @default.
- W2232423692 creator A5081348202 @default.
- W2232423692 creator A5090974164 @default.
- W2232423692 date "2007-06-20" @default.
- W2232423692 modified "2023-09-26" @default.
- W2232423692 title "A pilot study of myeloablative (MA) autologous stem Cell (Auto SCT) followed by reduced intensity (RI) allogeneic transplantation (AlloSCT) in children with relapsed/refractory(R/R) Hodgkin’s disease (HD)" @default.
- W2232423692 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.20007" @default.
- W2232423692 hasPublicationYear "2007" @default.
- W2232423692 type Work @default.
- W2232423692 sameAs 2232423692 @default.
- W2232423692 citedByCount "0" @default.
- W2232423692 crossrefType "journal-article" @default.
- W2232423692 hasAuthorship W2232423692A5001697191 @default.
- W2232423692 hasAuthorship W2232423692A5019068922 @default.
- W2232423692 hasAuthorship W2232423692A5033104475 @default.
- W2232423692 hasAuthorship W2232423692A5048733835 @default.
- W2232423692 hasAuthorship W2232423692A5049279048 @default.
- W2232423692 hasAuthorship W2232423692A5051296786 @default.
- W2232423692 hasAuthorship W2232423692A5060384074 @default.
- W2232423692 hasAuthorship W2232423692A5066588983 @default.
- W2232423692 hasAuthorship W2232423692A5081348202 @default.
- W2232423692 hasAuthorship W2232423692A5090974164 @default.
- W2232423692 hasConcept C121332964 @default.
- W2232423692 hasConcept C126322002 @default.
- W2232423692 hasConcept C141071460 @default.
- W2232423692 hasConcept C142424586 @default.
- W2232423692 hasConcept C143998085 @default.
- W2232423692 hasConcept C2779050716 @default.
- W2232423692 hasConcept C2779338263 @default.
- W2232423692 hasConcept C28328180 @default.
- W2232423692 hasConcept C2911091166 @default.
- W2232423692 hasConcept C54355233 @default.
- W2232423692 hasConcept C71924100 @default.
- W2232423692 hasConcept C86803240 @default.
- W2232423692 hasConcept C87355193 @default.
- W2232423692 hasConcept C90924648 @default.
- W2232423692 hasConceptScore W2232423692C121332964 @default.
- W2232423692 hasConceptScore W2232423692C126322002 @default.
- W2232423692 hasConceptScore W2232423692C141071460 @default.
- W2232423692 hasConceptScore W2232423692C142424586 @default.
- W2232423692 hasConceptScore W2232423692C143998085 @default.
- W2232423692 hasConceptScore W2232423692C2779050716 @default.
- W2232423692 hasConceptScore W2232423692C2779338263 @default.
- W2232423692 hasConceptScore W2232423692C28328180 @default.
- W2232423692 hasConceptScore W2232423692C2911091166 @default.
- W2232423692 hasConceptScore W2232423692C54355233 @default.
- W2232423692 hasConceptScore W2232423692C71924100 @default.
- W2232423692 hasConceptScore W2232423692C86803240 @default.
- W2232423692 hasConceptScore W2232423692C87355193 @default.
- W2232423692 hasConceptScore W2232423692C90924648 @default.
- W2232423692 hasLocation W22324236921 @default.
- W2232423692 hasOpenAccess W2232423692 @default.
- W2232423692 hasPrimaryLocation W22324236921 @default.
- W2232423692 hasRelatedWork W1955322177 @default.
- W2232423692 hasRelatedWork W2053613610 @default.
- W2232423692 hasRelatedWork W2118322536 @default.
- W2232423692 hasRelatedWork W2183051705 @default.
- W2232423692 hasRelatedWork W2360634842 @default.
- W2232423692 hasRelatedWork W2498568625 @default.
- W2232423692 hasRelatedWork W2597150331 @default.
- W2232423692 hasRelatedWork W2889487705 @default.
- W2232423692 hasRelatedWork W3174720739 @default.
- W2232423692 hasRelatedWork W3180209262 @default.
- W2232423692 isParatext "false" @default.
- W2232423692 isRetracted "false" @default.
- W2232423692 magId "2232423692" @default.
- W2232423692 workType "article" @default.